This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Is Immunotherapy the Next Hot Industry for Biotech Stock Investors?
by Eric Dutram
In this edition of the Dutram Report, Eric Dutram talks with Brad Loncar, the CEO of Loncar Investments who specializes in the world of immunotherapy. This approach is revolutionizing the cancer treatment market, and we get to the bottom of this emerging technology in the podcast so that investors can better understand why this market may deserve a closer look.
Zacks Industry Outlook Highlights: Amgen, Vertex, Valeant Pharmaceuticals International, Mylan N.V. and Gilead Sciences
by Zacks Equity Research
Zacks Industry Outlook Highlights: Amgen, Vertex, Valeant Pharmaceuticals International, Mylan N.V. and Gilead Sciences
Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen
by Zacks Equity Research
Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen
Fundamentals Remain Strong in the Pharma Sector
by Arpita Dutt
We could see several M&A agreements being announced in the coming quarters, though companies are wary of bidding wars leading to over-priced deals.
Pricing Issues Continue to Weigh on the Pharma Sector
by Zacks Equity Research
With generics and biosimilars on the rise, many pharma companies are looking towards new products to pick up the pace and make up for lost sales.
Pharma Industry Outlook - November 2016
by Arpita Dutt
It's been a rough year for pharma and biotech stocks, with media and political focus on the high price of drugs, mixed performance results, slower-than-expected new product launches and increasing competition.
Stock Market News for October 12, 2016
by Zacks Equity Research
Disappointing start to the third quarter earnings season weighed on benchmarks on Tuesday
6 Healthcare Stocks Investors Cannot Miss in Q3 Earnings
by Zacks Equity Research
A number of healthcare companies are recording improvements in their financial numbers.
Stock Market News for September 15, 2016
by Zacks Equity Research
Both the Dow and the S&P 500 closed in the red on Wednesday, thanks to a slump in crude-oil prices
Top Research Reports for September 2, 2016
by Sheraz Mian
Today's must-read reports are for Amgen (AMGN), HSBC (HSBC) and Broadcom (AVGO).
Stock Market News for August 09, 2016
by Zacks Equity Research
Despite strong crude rally, major benchmarks closed in the red on Monday on the back of declines in healthcare stocks
Top 7 Research Reports for July 29, 2016
by Sheraz Mian
Today's must-read reports are for Amgen (AMGN), JPMorgan (JPM) and Mondelez (MDLZ).
Pharma Industry Outlook: Fundamentals Remain Strong
by Arpita Dutt
It's been a rough start to the year for pharma and biotech with several factors weighing on the sector.
Top 6 Research Reports for June 29, 2016
by Sheraz Mian
Today's must-read reports are for Amgen (AMGN), Kraft Heinz (KHC) and United Parcel (UPS).
by Zacks Equity Research
The biotech segment has been growing well surpassing all expectations.